Grönroos M, Kangas L, Mäenpää J, Vanharanta R, Paul R
Br J Obstet Gynaecol. 1984 May;91(5):479-82. doi: 10.1111/j.1471-0528.1984.tb04787.x.
Samples of 21 ovarian cancers were assayed for oestrogen receptor (ER) and progesterone receptor (PR) content, and the response in vitro to treatment with a combination of doxorubicin, diacetyldian hydrogalactitol and cisplatin was determined. The number of living cells after drug exposure was estimated by a new ATP-bioluminescence method and the tumours were considered responsive if cell survival was less than or equal to 50% of the value in a corresponding control culture. Of the 16 tumours that responded to drug exposure, nine were ER-positive, seven ER-negative and eight were PR-positive, eight PR-negative. The mean percentages of surviving cells ranged from 22.2% in PR-negative tumours to 30.9% in PR-positive tumours. There were no differences in the response rates or in the degree of response to the cytostatics in terms of either receptor status or tumour histology. The results were also compared with those obtained in the same tumour samples exposed to hormones, tamoxifen and medroxyprogesterone acetate. The average response of all tumours was better to cytostatics than to hormones (P less than 0.05); this was particularly marked in the ER-negative tumours. Cytostatics may be preferable to hormones as the primary drug treatment for ovarian cancers but steroid-receptor determinations appear not to help in formulating the optimum drug treatment.
对21例卵巢癌样本进行雌激素受体（ER）和孕激素受体（PR）含量检测，并确定其对阿霉素、双乙酰脱氢半乳糖醇和顺铂联合治疗的体外反应。药物暴露后活细胞数量通过一种新的ATP生物发光法进行估算，如果细胞存活率小于或等于相应对照培养物中细胞存活率的50%，则认为肿瘤有反应。在对药物暴露有反应的16例肿瘤中，9例为ER阳性，7例为ER阴性，8例为PR阳性，8例为PR阴性。存活细胞的平均百分比范围从PR阴性肿瘤中的22.2%到PR阳性肿瘤中的30.9%。无论是受体状态还是肿瘤组织学，在反应率或对细胞抑制剂的反应程度方面均无差异。还将结果与在相同肿瘤样本中暴露于激素、他莫昔芬和醋酸甲羟孕酮后获得的结果进行比较。所有肿瘤对细胞抑制剂的平均反应比对激素的反应更好（P<0.05）；这在ER阴性肿瘤中尤为明显。对于卵巢癌，细胞抑制剂作为主要药物治疗可能比激素更可取，但类固醇受体测定似乎无助于制定最佳药物治疗方案。
